127 related articles for article (PubMed ID: 1721349)
1. Liver retransplantation in adults: overall results and determinant factors affecting the outcome.
Morel P; Rilo HL; Tzakis AG; Todo S; Gordon RD; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3029-31. PubMed ID: 1721349
[No Abstract] [Full Text] [Related]
2. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection.
Wiesner RH; Porayko MK; Wahlstrom HE; Gores GJ; Kamath PS; Hay JE; Krom RA
Transplant Proc; 1993 Apr; 25(2):1791-3. PubMed ID: 7682352
[No Abstract] [Full Text] [Related]
3. Renal function in primary liver transplant recipients receiving neoral (cyclosporine) versus prograf (tacrolimus).
Van Buren D; Payne J; Geevarghese S; MacDonell R; Chapman W; Wright JK; Helderman JH; Richie R; Pinson CW
Transplant Proc; 1998 Jun; 30(4):1401-2. PubMed ID: 9636566
[TBL] [Abstract][Full Text] [Related]
4. Recurrent rejection following FK 506 rescue therapy for acute hepatic allograft rejection.
Woodle ES; So S; Jendrisak MD; Perdrizet GA; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1988-9. PubMed ID: 7682358
[No Abstract] [Full Text] [Related]
5. Combined orthotopic liver-small bowel transplantation or small bowel transplantation in pigs: relations between survival, rejection, and mucosal morphometry.
Velio P; Bardella MT; Bertoglio ; Rossi G; Gatti S; Fassati LR
Transplant Proc; 1997 May; 29(3):1840-1. PubMed ID: 9142295
[No Abstract] [Full Text] [Related]
6. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression.
Ghobrial RM; Colquhoun S; Rosen H; Hollis P; Ponthieux S; Pakrasi A; Farmer DG; Markman JF; Markowitz J; Drazan K; Yersiz H; Singer J; Stribling R; Arnout W; Holt CD; Goss J; Imagawa D; Seu P; Goldstein LI; Shackleton CR; Martin P; Busuttil RW
Transplant Proc; 1998 Jun; 30(4):1470-1. PubMed ID: 9636597
[No Abstract] [Full Text] [Related]
7. FK 506 versus cyclosporine in pediatric liver transplantation.
Tzakis AG; Reyes J; Todo S; Green M; Ohya T; Jain A; Abu-Elmagd K; Alessiani M; Fung JJ; Starzl TE
Transplant Proc; 1991 Dec; 23(6):3010-5. PubMed ID: 1721343
[No Abstract] [Full Text] [Related]
8. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong.
Lo CM; Fan ST; Liu CL; Chan KL; Ng IO; Lai CL; Lau GK; Fung SK; Wong J
Transplant Proc; 1998 Nov; 30(7):3587-8. PubMed ID: 9838571
[No Abstract] [Full Text] [Related]
9. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation.
Rafecas A; Lladó L; Albiol MT; Ramos E; Torras J; Fabregat J; Lama C; Busquets J; Ibáñez L; Figueras J; Jaurrieta E
Transplant Proc; 2002 Feb; 34(1):107. PubMed ID: 11959209
[No Abstract] [Full Text] [Related]
10. FK 506 rescue therapy: the rapidity of rejection reversal is related to the subsequent development of CMV disease.
Woodle ES; Perdrizet GA; So S; Jendrisak MD; White HM; Marsh JW
Transplant Proc; 1993 Apr; 25(2):1992-3. PubMed ID: 7682360
[No Abstract] [Full Text] [Related]
11. Comparative long-term evaluation of tacrolimus and cyclosporine in pediatric liver transplantation.
Jain A; Mazariegos G; Kashyap R; Green M; Gronsky C; Starzl TE; Fung J; Reyes J
Transplantation; 2000 Aug; 70(4):617-25. PubMed ID: 10972220
[TBL] [Abstract][Full Text] [Related]
12. Weaning of immunosuppression in liver transplant recipients.
Mazariegos GV; Reyes J; Marino IR; Demetris AJ; Flynn B; Irish W; McMichael J; Fung JJ; Starzl TE
Transplantation; 1997 Jan; 63(2):243-9. PubMed ID: 9020325
[TBL] [Abstract][Full Text] [Related]
13. Rejection: FK 506 for rescue or maintenance.
Klintmalm GB; Gibbs JF; McMillan R; Backman L; Levy M; Goldstein RM; Husberg BS; Holman MJ; Gonwa TA
Transplant Proc; 1993 Apr; 25(2):1914-5. PubMed ID: 7682356
[No Abstract] [Full Text] [Related]
14. Rejection and tacrolimus conversion therapy in paediatric liver transplantation.
Spada M; Corno V; Colledan M; Segalin A; Lucianetti A; Torre G; Riva S; Sonzogni A; Petz W; Gridelli B
Transpl Int; 2000; 13 Suppl 1():S341-4. PubMed ID: 11112028
[TBL] [Abstract][Full Text] [Related]
15. FK506 for primary and rescue therapy following liver transplantation.
Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
[No Abstract] [Full Text] [Related]
16. Is the use of marginal liver grafts justified?
Mueller AR; Platz KP; Krause P; Steinmüller T; Glanemann M; Neumann U; Lobeck H; Neuhaus P
Transplant Proc; 1999; 31(1-2):401-2. PubMed ID: 10083160
[No Abstract] [Full Text] [Related]
17. Outcome following orthotopic liver transplantation in HBsAg-positive patients using short- or long-term immunoprophylaxis.
Lemmens HP; Langrehr JM; Blumhardt G; Lohmann R; Knoop M; Verschl J; Schattenfroh N; Neuhaus R; Hopf U; Bechstein WO
Transplant Proc; 1994 Dec; 26(6):3622-3. PubMed ID: 7527983
[No Abstract] [Full Text] [Related]
18. Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.
Bismuth H
Transplant Proc; 1995 Feb; 27(1):45-9. PubMed ID: 7533415
[No Abstract] [Full Text] [Related]
19. Graft-versus-host reaction and graft rejection after liver, small bowel or small bowel allotransplantation in the pig.
Gatti S; Ghidoni P; Rossi G; Cobalti B; Latham L; Doglia M; Galmarini D; Fassati LR
Transplant Proc; 1998 Sep; 30(6):2601-4. PubMed ID: 9745509
[No Abstract] [Full Text] [Related]
20. Treatment of acute renal transplant rejection with FK 506 in patients on cyclosporine after failure of standard antirejection therapy.
Scott-Douglas N; Zimmerman D; Klassen J
Transplant Proc; 1996 Dec; 28(6):3165. PubMed ID: 8962226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
